Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nuno Taveira

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
AIDS (London, England)|November 26, 2019
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapyInês Moranguinho, Pedro Borrego, Fátima Gonçalves, et al.
AIDS Research and Human Retroviruses|June 10, 2005
High genetic diversity of human immunodeficiency virus type 1 in AngolaInês Bártolo, Marta Epalanga, José Bartolomeu, et al.
Plos One|February 2, 2011
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infectionHelena Barroso, Pedro Borrego, Inês Bártolo, et al.
Journal of Virology|September 17, 2010
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategyJosé Maria Marcelino, Pedro Borrego, Cheila Rocha, et al.
Antiviral Research|November 5, 2018
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2Inês Bártolo, Pedro Borrego, Perpétua Gomes, et al.
AIDS (London, England)|January 18, 2013
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activityPedro Borrego, Rita Calado, José M Marcelino, et al.
Journal of Clinical Microbiology|July 5, 2003
Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant formsRute Antunes, Sofia Figueiredo, Inês Bártolo, et al.
AIDS (London, England)|February 13, 2024
HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape VerdePaloma Gonçalves, Jorge Barreto, Menilita Santos, et al.
AIDS (London, England)|April 21, 2004
Seronegative infection and AIDS caused by an A2 subsubtype HIV-1Ana R Cardoso, Cristina Gonçalves, Dulce Pascoalinho, et al.
Journal of Virology|September 30, 2016
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 IsolatesChia-Yen Chen, Masashi Shingai, Sarah Welbourn, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
AIDS (London, England)|November 26, 2019
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapyInês Moranguinho, Pedro Borrego, Fátima Gonçalves, et al.
AIDS Research and Human Retroviruses|June 10, 2005
High genetic diversity of human immunodeficiency virus type 1 in AngolaInês Bártolo, Marta Epalanga, José Bartolomeu, et al.
Plos One|February 2, 2011
Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infectionHelena Barroso, Pedro Borrego, Inês Bártolo, et al.
Journal of Virology|September 17, 2010
Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategyJosé Maria Marcelino, Pedro Borrego, Cheila Rocha, et al.
Antiviral Research|November 5, 2018
In vitro evaluation of novel reverse transcriptase inhibitors TAF (tenofovir alafenamide) and OBP-601 (2,3-didehydro-3-deoxy-4-ethynylthymidine) against multi-drug resistant primary isolates of HIV-2Inês Bártolo, Pedro Borrego, Perpétua Gomes, et al.
AIDS (London, England)|January 18, 2013
An ancestral HIV-2/simian immunodeficiency virus peptide with potent HIV-1 and HIV-2 fusion inhibitor activityPedro Borrego, Rita Calado, José M Marcelino, et al.
Journal of Clinical Microbiology|July 5, 2003
Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant formsRute Antunes, Sofia Figueiredo, Inês Bártolo, et al.
AIDS (London, England)|February 13, 2024
HIV-1 drug resistance and genetic diversity in people with HIV-1 in Cape VerdePaloma Gonçalves, Jorge Barreto, Menilita Santos, et al.
AIDS (London, England)|April 21, 2004
Seronegative infection and AIDS caused by an A2 subsubtype HIV-1Ana R Cardoso, Cristina Gonçalves, Dulce Pascoalinho, et al.
Journal of Virology|September 30, 2016
Antagonism of BST-2/Tetherin Is a Conserved Function of the Env Glycoprotein of Primary HIV-2 IsolatesChia-Yen Chen, Masashi Shingai, Sarah Welbourn, et al.
Pageof 9